OCUGEN ($OCGN) posted quarterly earnings results for Q4 2025 on Wednesday, March 4th. The company reported earnings of -$0.06 per share, missing estimates of -$0.06 by $0.00. The company also reported revenue of $-190,000, missing estimates of $877,200 by $-1,067,200.
You can see Quiver Quantitative's $OCGN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
OCUGEN Hedge Fund Activity
We have seen 63 institutional investors add shares of OCUGEN stock to their portfolio, and 55 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GMT CAPITAL CORP removed 4,153,798 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $5,607,627
- UBS GROUP AG added 3,824,474 shares (+373.2%) to their portfolio in Q4 2025, for an estimated $5,163,039
- STATE STREET CORP added 2,623,361 shares (+193.6%) to their portfolio in Q4 2025, for an estimated $3,541,537
- MARSHALL WACE, LLP added 2,530,956 shares (+inf%) to their portfolio in Q4 2025, for an estimated $3,416,790
- GOLDMAN SACHS GROUP INC added 2,204,765 shares (+2256.4%) to their portfolio in Q4 2025, for an estimated $2,976,432
- CUBIST SYSTEMATIC STRATEGIES, LLC removed 1,587,872 shares (-95.3%) from their portfolio in Q3 2025, for an estimated $2,588,231
- RENAISSANCE TECHNOLOGIES LLC added 1,410,200 shares (+485.9%) to their portfolio in Q4 2025, for an estimated $1,903,770
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
OCUGEN Analyst Ratings
Wall Street analysts have issued reports on $OCGN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Chardan Capital issued a "Buy" rating on 01/20/2026
To track analyst ratings and price targets for OCUGEN, check out Quiver Quantitative's $OCGN forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
